Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16853028 | 1.00 | ALDH1A1 (0.65) | ALDH1A1TDP1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL16853067 | 1.00 | ALDH1A1 (0.65) | ALDH1A1TDP1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL18135609 | 1.00 | ALDH1A1 (0.65) | ALDH1A1TDP1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL18135612 | 1.00 | ALDH1A1 (0.65) | ALDH1A1TDP1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL16834667 | 0.94 | ALDH1A1 (0.71) | ALDH1A1TDP1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL16853084 | 0.94 | ALDH1A1 (0.71) | ALDH1A1TDP1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL16834836 | 0.94 | ALDH1A1 (0.71) | ALDH1A1TDP1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL16834544 | 0.94 | ALDH1A1 (0.71) | ALDH1A1TDP1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL16834772 | 0.94 | ALDH1A1 (0.71) | ALDH1A1TDP1SMN1; SMN2TSHRMEN1 | |
| SCHEMBL16834837 | 0.94 | ALDH1A1 (0.71) | ALDH1A1TDP1SMN1; SMN2TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233358-A1 | MONO- AND DIALKYL ETHERS OF FURAN-2,5-DIMETHANOL AND (TETRA-HYDROFURAN-2,5-DIYL)DIMETHANOL AND AMPHIPHILIC DERIVATIVES THEREOF | ARCHER DANIELS MIDLAND COMPANY | 2017-08-17 | — | — | US | disclosed |
| US-9670174-B2 | Mono- and dialkyl ethers of furan-2,5-dimethanol and (tetra-hydrofuran-2,5-diyl)dimethanol and amphiphilic derivatives thereof | ARCHER DANIELS MIDLAND COMPANY (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160297785-A1 | MONO- AND DIALKYL ETHERS OF FURAN-2,5-DIMETHANOL AND (TETRA-HYDROFURAN-2,5-DIYL)DIMETHANOL AND AMPHIPHILIC DERIVATIVES THEREOF | ARCHER DANIELS MIDLAND CO (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2015094970-A1 | MONO- AND DIALKYL ETHERS OF FURAN-2,5-DIMETHANOL AND (TETRA-HYDROFURAN-2,5-DIYL)DIMETHANOL AND AMPHIPHILIC DERIVATIVES THEREOF | ARCHER DANIELS MIDLAND COMPANY (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233358-A1 | MONO- AND DIALKYL ETHERS OF FURAN-2,5-DIMETHANOL AND (TETRA-HYDROFURAN-2,5-DIYL)DIMETHANOL AND AMPHIPHILIC DERIVATIVES THEREOF | DTYMK, DGKA, DGKK | ALDH1A1 1895/4885TDP1 1509/4885SMN1; SMN2 4602/4885 |
| US-20160297785-A1 | MONO- AND DIALKYL ETHERS OF FURAN-2,5-DIMETHANOL AND (TETRA-HYDROFURAN-2,5-DIYL)DIMETHANOL AND AMPHIPHILIC DERIVATIVES THEREOF | DTYMK, DBF4, DIMT1 | ALDH1A1 1599/4885TDP1 855/4885SMN1; SMN2 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.